Brief: Revive Therapeutics Provides Update On FDA Type C Meeting For Clinical Study Of Bucillamine To Treat Long Covid
12/06/2024 14:32
June 12 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE ON FDA TYPE C MEETING
FOR
CLINICAL STUDY OF BUCILLAMINE TO TREAT LONG COVID
* REVIVE THERAPEUTICS LTD - FDA HAS RECOMMENDED THAT
EVALUATION OF
BUCILLAMINE FOR LONG COVID BE SUBMITTED AS A NEW IND APPLICATION
* REVIVE THERAPEUTICS LTD - COMPANY IS EXPLORING USE OF
BUCILLAMINE AS A POTENTIAL TREATMENT FOR LONG COVID
* REVIVE THERAPEUTICS LTD - ADDITIONAL PHASE 3 CLINICAL
TRIAL DATA
ANALYSES MAY SUGGEST BUCILLAMINE'S POTENTIAL FOR LONG COVID.
Source text for Eikon: ID:nGNX3BGqxw
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure